Hershfield, M. S., Sundy, J. S., Ganson, N. J., & Kelly, S. J. (2009). Development of PEGylated mammalian urate oxidase as a therapy for patients with refractory gout. In PEGylated Protein Drugs: Basic Science and Clinical Applications (pp. 217–227). Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-8679-5_13

Hershfield, Michael S., John S. Sundy, Nancy J. Ganson, and Susan J. Kelly. “Development of PEGylated mammalian urate oxidase as a therapy for patients with refractory gout.” In PEGylated Protein Drugs: Basic Science and Clinical Applications, 217–27. Birkhäuser Basel, 2009. https://doi.org/10.1007/978-3-7643-8679-5_13.

Hershfield MS, Sundy JS, Ganson NJ, Kelly SJ. Development of PEGylated mammalian urate oxidase as a therapy for patients with refractory gout. In: PEGylated Protein Drugs: Basic Science and Clinical Applications. Birkhäuser Basel; 2009. p. 217–27.

Hershfield, Michael S., et al. “Development of PEGylated mammalian urate oxidase as a therapy for patients with refractory gout.” PEGylated Protein Drugs: Basic Science and Clinical Applications, Birkhäuser Basel, 2009, pp. 217–27. Crossref, doi:10.1007/978-3-7643-8679-5_13.

Hershfield MS, Sundy JS, Ganson NJ, Kelly SJ. Development of PEGylated mammalian urate oxidase as a therapy for patients with refractory gout. PEGylated Protein Drugs: Basic Science and Clinical Applications. Birkhäuser Basel; 2009. p. 217–227.